Open-label, Single-center Phase II Study of MLN9708 (Ixazomib) in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2016
At a glance
- Drugs Ixazomib (Primary)
- Indications T cell lymphoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 12 May 2015 Planned primary completion date changed from 1 Aug 2018 to 1 Sep 2018 as reported by ClinicalTrials.gov record.